From weight loss buzz to healthcare infrastructure, GLP-1 drugs started as diabetes treatments but are now reshaping weight loss, care delivery, and consumer markets. In this episode, we explore how they have become more than medicine, driving new business models, digital access points, and patient expectations, featuring insights from leaders across health plans, startups, and strategy firms.
